接受Hyper-CVAD联合达沙替尼或帕纳替尼治疗的费城染色体阳性急性淋巴细胞白血病患者的遗传学相关因素
该研究系统分析了接受Hyper-CVAD联合达沙替尼或帕纳替尼方案治疗的成人费城染色体阳性急性淋巴细胞白血病患者的遗传学改变,发现84%的患者存在反复出现的遗传学异常,其中IKZF1缺失最常见(60%)。IKZF1缺失与不良总生存期显著相关(错误发现率<0.1),且与复发累积发生率增加相关(p=0.01)。多因素分析显示,达沙替尼治疗、未达到3个月完全分子学缓解以及IKZF1plus状态与较差的总生存期显著相关。
要点
- 84%的费城染色体阳性急性淋巴细胞白血病患者存在反复遗传学异常,IKZF1缺失最常见(60%)。
- IKZF1缺失与不良总生存期显著相关(错误发现率<0.1),并增加复发累积发生率(p=0.01)。
- 多因素分析中,达沙替尼治疗、未达3个月完全分子学缓解及IKZF1plus状态与较差总生存期显著相关。
核心结论
- 在费城染色体阳性急性淋巴细胞白血病成人患者中,IKZF1缺失常见并与不良预后相关,IKZF1plus状态与接受帕纳替尼方案患者的不良总生存期相关。
研究设计与样本
- 研究系统分析了在临床试验中统一接受达沙替尼为基础方案或帕纳替尼为基础方案治疗的成人费城染色体阳性急性淋巴细胞白血病患者的遗传学改变,使用治疗前标本进行DNA测序和SNP微阵列分析。
主要发现
- 84%的患者发现反复遗传学异常,其中IKZF1缺失最常见(60%)。
- IKZF1缺失常与其他拷贝数异常共存(IKZF1plus,46%),并与不良总生存期显著相关(错误发现率<0.1)及复发累积发生率增加相关(p=0.01)。
- 多因素分析显示,达沙替尼治疗、未达到3个月完全分子学缓解以及IKZF1plus状态与较差的总生存期显著相关。
- IKZF1plus的差异影响主要局限于接受Hyper-CVAD联合帕纳替尼治疗的患者;以达沙替尼为基础的方案无论分子异常如何均预后不佳。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recurring genetic abnormalities have been identified in Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). Among them, IKZF1 deletion was associated with poor prognosis in patients treated with imatinib-based or dasatinib-based regimens. However, the molecular determinants for clinical outcomes in ponatinib-treated patients remain unknown. We systematically analyzed genetic alterations in adults with Ph-positive ALL uniformly treated in clinical trials with dasatinib-based regimens or a ponatinib-based regimen and investigated the molecular determinants for treatment outcomes using pretreatment specimens collected from adults with Ph-positive ALL treated with Hyper-CVAD plus dasatinib or ponatinib. DNA sequencing and SNP microarray were performed and recurrent genetic abnormalities were found in 84% of the patients, among whom IKZF1 deletion was most frequently detected (60%). IKZF1 deletion frequently co-occurred with other copy-number abnormalities (IKZF1plus, 46%) and was significantly associated with unfavorable overall survival (OS) (false discovery rate < 0.1) and increased cumulative incidence of relapse (p = 0.01). In a multivariate analysis, dasatinib therapy, lack of achievement of 3-month complete molecular response, and the presence of IKZF1plus status were significantly associated with poor OS. The differential impact of IKZF1plus was largely restricted to patients given Hyper-CVAD plus ponatinib; dasatinib-based regimens had unfavorable outcomes regardless of the molecular abnormalities.
引用
- Sasaki Y, Kantarjian HM, Short NJ, et al. Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia. 2022. PMID: 35132195. doi:10.1038/s41375-021-01496-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。